Impact of donor-specific antibodies on long-term graft survival with pediatric liver transplantation

Table 3 Immunosuppressive therapy

Group 1 ‘DSA-positive’		Group 2 ‘DSA-negative’
Monotherapy	n = 29	n = 39
CSA	n = 17	n = 20
Trough level	109.5 µg/L (23-674 µg/L) median 73 µg/L	58.0 µg/L (29-106 µg/L)
TAC	n = 10	n = 17
Trough level	4.4µg/L (1.0-7.3 µg/L)	5.5 µg/L (2.6-7.7 µg/L)
EVE		n = 1
Trough level		10.3 µg/L
SIR	n = 1
Trough level	5.2 µg/L
MMF	n = 1	n = 1
Combined therapy	n = 25	n = 30
CSA
+ EVE	n = 3	n = 4
+ MMF	n = 3	n = 3
+ PRED	n = 2	n = 1
+ EVE + PRED		n = 1
+ MMF + PRED	n = 2
Trough level	54.7µg/L (11-89 µg/L)	72.7 µg/L (23-137 µg/L)
TAC
+ EVE	n = 3	n = 6
+ MMF	n = 5	n = 7
+ PRED	n = 5	n = 3
+ MMF + PRED	n = 1	n = 3
Trough level	6.1 µg/L (3.0-9.9 µg/L)	6.3 µg/L (2.1-15.1 µg/L)
EVE
+ MMF		n = 1
+ MMF + PRED	n = 1
Trough level	3.7 µg/L (1.0-5.0 µg/L)	4.3 µg/L (1.8-7.8 µg/L)
SIR
+ MMF		n = 1 (trough levels, NA)
Adherence rates
CSA	81.5%	72.4%
TAC	87.5%	88.9%
EVE	75%	84.9%
SIR	100%	100%

Trough levels given as mean (and range). MMF: Mycophenolate mofetil; CSA: Cyclosporin A; TAC: Tacrolimus; EVE: Everolimus; PRED: Prednisolone; SIR: Sirolimus; NA: Not available; DSA: Donor-specific antibodies.